Australia's most trusted
source of pharma news
Tuesday, 26 November 2024
Posted 22 November 2024 AM
Bayer's Nubeqa has officially hit blockbuster status, largely compensating for the drop in revenue from Xarelto in the third quarter of this year.
In the first nine months of 2024, global sales of Bayer's androgen receptor inhibitor used to treat prostate cancer earned 1,080 million euros in revenue. That equates to US$1.14 billion, confirming that Nubeqa has hit blockbuster status. Last year it came close, earning 869 million euros (US$916.7 million) for the full year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.